Central Asian Research Index

Journal of Clinical Medicine of Kazakhstan, 2026, т. 23, № 2, с. 51-56

Cytogenetic Characteristics and Treatment Outcomes of Congenital Acute Leukemia in Children in Kazakhstan: Retrospective Study

Saule Nukusheva, Almagul Saduova, Aman Berkinbay, Samal Aliyeva, Dana Zauytbek, Akerke Azanbai, Aygerim Ayazova, Araylym Abduali, Aiya Slamkhan, Anel Daber

JSC «Asfendiyarov Kazakh National Medical University», Almaty, Kazakhstan; JSC Scientific Center of Pediatrics and Pediatric Surgery, Almaty, Republic of Kazakhstan
JSC «Asfendiyarov Kazakh National Medical University», Almaty, Kazakhstan

Аннотация · Abstract

<b>Background: </b>Congenital acute leukemia (CAL) is a rare and aggressive hematologic malignancy diagnosed within the first 28 days of life. Cytogenetic abnormalities are essential for risk stratification and prognosis, but data on CAL in Kazakhstan remain limited.<br /> <b>Objective: </b>To describe cytogenetic characteristics and evaluate their association with treatment outcomes in children with congenital and early infant acute leukemia treated at a tertiary pediatric center in Kazakhstan.<br /> <b>Methods: </b>This retrospective single-center study included 33 children treated between 2018 and 2023 at the Scientific Center of Pediatrics and Pediatric Surgery (Almaty, Kazakhstan). Patients were classified as true CAL (diagnosis ≤28 days) or early infant leukemia (&gt;28 days). Cytogenetic findings, treatment protocols, remission, relapse, mortality, treatment-related toxicity, and survival were analyzed. Overall survival (OS) and event-free survival (EFS) were assessed using the Kaplan–Meier method.<br /> <b>Results: </b>Cytogenetic abnormalities were detected in 17/33 patients (51.5%). Favorable abnormalities included t(12;21), t(8;21), and inv(16), whereas unfavorable abnormalities included t(4;11)/KMT2A-rearranged leukemia and t(9;22). Complete remission after induction was achieved in 66.7% of patients and was significantly more frequent in the favorable cytogenetic group than in the unfavorable group (91.6% vs. 58.3%; p = 0.019). Treatment-related toxicity occurred in 42.4% of patients and was more common among those with non-complete remission (83.3% vs. 31.8%; p = 0.017). Estimated 2-year OS was 83.3% in the favorable cytogenetic group and 50.0% in the unfavorable group, while estimated 2-year EFS was 75.0% and 41.7%, respectively. Survival differed significantly according to cytogenetic risk (log-rank p = 0.032 for OS; p = 0.021 for EFS).<br /> <b>Conclusion: </b>Congenital and early infant acute leukemia in this single-center cohort from Kazakhstan demonstrated substantial cytogenetic heterogeneity associated with remission and survival outcomes. Cytogenetic-based risk stratification and careful management of treatment-related toxicity may improve outcomes in this vulnerable patient population.

Сведения · Details